Gender disparities in the tumor genetics and clinical outcome of multiple myeloma

Cancer Epidemiology Biomarkers and Prevention

Volumn 20, Issue 8, 2011, Pages 1703-1707

  Boyd, Kevin D ^a   Ross, Fiona M ^b   Chiecchio, Laura ^b   Dagrada, GianPaolo ^b   Konn, Zoe J ^b   Tapper, William J ^b   Walker, Brian A ^a   Wardell, Christopher P ^a   Gregory, Walter M ^c   Szubert, Alex J ^c   Davies, Faith E ^a   Morgan, Gareth J ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER GENETICS; CANCER PATIENT; CONTROLLED STUDY; DIPLOIDY; DISEASE ASSOCIATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE TRANSLOCATION; HUMAN; IMMUNOGLOBULIN HEAVY CHAIN GENE; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PREVALENCE; PRIORITY JOURNAL; SEX DIFFERENCE;

ADULT; AGED; AGED, 80 AND OVER; CHROMOSOME ABERRATIONS; FEMALE; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PREVALENCE; SEX FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 79961227550     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-11-0157     Document Type: Article

References (25)

1. Oberaigner W, Siebert U. Do women with cancer have better survival as compared to men after adjusting for staging distribution? Eur J Public Health 2011;21:387-91.
2. Wisnivesky JP, Halm EA. Sex differences in lung cancer survival: do tumors behave differently in elderly women?J Clin Oncol 2007;25: 1705-12. (Pubitemid 46797951)
3. Mostertz W, Stevenson M, Acharya C, Chan I, Walters K, Lamlertthon W, et al. Age- and sex-specific genomic profiles in non-small cell lung cancer. JAMA 2010;303:535-43.
4. Gonzalez D, van der Burg M, Garcia-Sanz R, Fenton JA, Langerak AW, Gonzalez M, et al. Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. Blood 2007;110:3112-21. (Pubitemid 350106301)
5. Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK, et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009; 23:2210-21.
6. Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 2005;23:6333-8. (Pubitemid 46218843)
7. Fonseca R, Debes-Marun CS, Picken EB, Dewald GW, Bryant SC, Winkler JM, et al. The recurrent IgH translocations are highly associated with non-hyperdiploid variant multiple myeloma. Blood 2003;102:2562-7. (Pubitemid 37193596)
8. Walker BA, Leone PE, Jenner MW, Li C, Gonzalez D, Johnson DC, et al. Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma. Blood 2006;108:1733-43. (Pubitemid 44316144)
9. Leone PE, Walker BA, Jenner MW, Chiecchio L, Dagrada G, Protheroe RK, et al. Deletions of CDKN2C in multiple myeloma: biological and clinical implications. Clin Cancer Res 2008;14:6033-41.
10. Walker BA, Leone PE, Chiecchio L, Dickens NJ, Jenner MW, Boyd KD, et al. A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood 2010;116: e56-65.
11. Vachon CM, Kyle RA, Therneau TM, Foreman BJ, Larson DR, Colby CL, et al. Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance. Blood 2009;114:785-90.
12. Landgren O, Kristinsson SY, Goldin LR, Caporaso NE, Blimark C, Mellqvist UH, et al. Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden. Blood 2009;114:791-5.
13. Kristinsson SY, Bjorkholm M, Goldin LR, Blimark C, Mellqvist UH, Wahlin A, et al. Patterns of hematologic malignancies and solid tumors among 37,838 first-degree relatives of 13,896 patients with multiple myeloma in Sweden. Int J Cancer 2009;125:2147-50.
14. Bizzaro N, Pasini P. Familial occurrence of multiple myeloma and monoclonal gammopathy of undetermined significance in 5 siblings. Haematologica 1990;75:58-63. (Pubitemid 20138538)
15. Lynch HT, Ferrara K, Barlogie B, Coleman EA, Lynch JF, Weisenburger D, et al. Familial myeloma. N Engl J Med 2008;359:152-7. (Pubitemid 351962038)
16. Lynch HT, Thome SD. Familial multiple myeloma. Blood 2009;114: 749-50.
17. Altekruse SF KC, Krapcho M, Neyman N, Aminou R, Waldron W, Ruhl J, Howlader N, editors. SEER cancer statistics review, 1975-2007. Bethesda, MD: National Cancer Institute, NIH; 2010.
18. Landgren O, Rajkumar SV, Pfeiffer RM, Kyle RA, Katzmann JA, Dispenzieri A, et al. Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women. Blood 2010;116:1056-9.
19. Landgren O, Weiss BM. Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/ racial groups: support for genetic factors in pathogenesis. Leukemia 2009;23:1691-7.
20. Morgan GJ, Davies FE, Gregory WM, Cocks K, Bell SE, Szubert AJ, et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 2010;376:1989-99.
21. Chiecchio L, Protheroe RK, Ibrahim AH, Cheung KL, Rudduck C, Dagrada GP, et al. Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma. Leukemia 2006;20:1610-7. (Pubitemid 44264105)
22. Chiecchio L, Dagrada GP, Ibrahim AH, Dachs Cabanas E, Protheroe RK, Stockley DM, et al. Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context. Haematologica 2009;94:1708-13.
23. Terpos E, Katodritou E, Roussou M, Pouli A, Michalis E, Delimpasi S, et al. High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents. Eur J Haematol 2010;85:114-9.
24. Hosgood HD III, Baris D, Zhang Y, Berndt SI, Menashe I, Morton LM, et al. Genetic variation in cell cycle and apoptosis related genes and multiple myeloma risk. Leuk Res 2009;33:1609-14.
25. Purdue MP, Lan Q, Menashe I, Zheng T, Zhang Y, Yeager M, et al. Variation in innate immunity genes and risk of multiple myeloma. Hematol Oncol 2011;29:42-6.